BD PROJECTS
Product for Licensing
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!~
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
If you are looking for brain-penetrating JAK1/TYK2 inhibitors, please contact DrugTimes BD Team at BD@drugtimes.cn asap
If you are looking for similar products, please feel free to contact DrugTimes BD Team. We can help you find quality products and partners quickly
Request for Product
If your company is interested in this opportunity, please contact DrugTimes BD team as soon as possible!
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
Please contact the DrugTimes BD team as soon as possible!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
If your company is interested in this opportunity, please contact us as soon as possible!
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
Project ID: BP-20240430-L-EE-81 About IBD Inflammatory bowel disease (IBD) is a gro…
Please contact us. Our email address is BD@drugtimes.cn
Bio News
For more reports, please follow DrugTimes
Congratulations to Dr. Tie-Ling Wang and VastPro PharmaTech!
DrugTimes will continue to follow up and report in a timely manner
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
DrugTimes Team will keep updating this document in the coming days. All comments are highly welcome!~
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
Congratulations to GSK and Vesalius Therapeutics!
Congratulations to CSPC and AstraZeneca!
Congratulations to Sunshine Lake Pharma and Apollo Therapeutics!
Congratulations! This is the latest successful case of NewCo for China pharma and biotech companies
Congratulations to Chimagen and GSK!
The info will be updated in the coming days
Insights
This is an inspiring story of drug development for patients in great need
For more reports, please follow DrugTimes. Many thanks!
For more reports, please follow DrugTimes. Many thanks!
DrugTimes will continue to follow and report on this key topic
LIDNewCo=License In-Development-NewCo model, is the 2.0 version of NewCo
For more reports, please follow DrugTimes
To explore more efficient and stable clinical trial protocols, these “failures” are inevitably part of the cost
For more articles, please follow DrugTimes. Many thanks!
For more reports, please follow DrugTimes
It is believed that both WuXi AppTec and WuXi ATU will continue to exert greater energy for more innovators and patients in need in the future
One of President Carter’s most notable achievements was the formal establishment of diplomatic relations between China and the United States during his tenure
The video is available for watching, too. Please visit DrugTimes. Many thanks!~
